The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Dr. George D. Demetri on Trabectedin or Dacarbazine Treatments for Patients With Advanced Leiomyosarcoma or Liposarcoma

George D. Demetri, MD
Published Online: 8:14 PM, Thu November 5, 2015

George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses the trial the led to the approval of trabectedin (Yondelis) for advanced leiomyosarcoma or liposarcoma.

In this preplanned analysis, researchers were trying to limit any excess heterogeneity in order to get a clear answer as to whether trabectedin is more active than dacarbazine. There is no question, Demetri says, that there was a progression-free survival (PFS) difference but no overall survival (OS) difference.

Demetri says the lack of OS difference was due to post-study therapies — virtually all patients went on to receive other agents after this protocol. It's worth noting, he says, that the trial was designed in 2010 and pazopanib (Votrient) was approved in 2012.



Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.